A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Sponsor: Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Participating sites:
- UZ Leuven, Leuven
- CHU Ambroise Paré, Mons
- CHU UCL Namur, site Sainte Elisabeth, Namur
- CHU UCL St. Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU de Liège, site Sart Tilman, Liège